Skip to main content Back to Top
Advertisement

10/12/2020

Cisatracurium Besylate Injection

Products Affected - Description

    • Nimbex injection, AbbVie, 10 mg/mL, 20 mL vial, 10 count, NDC 00074-4382-20
    • Nimbex injection, AbbVie, 2 mg/mL, 10 mL vial, 10 count, NDC 00074-4380-10
    • Nimbex injection, AbbVie, 2 mg/mL, 5 mL vial, 10 count, NDC 00074-4378-05
    • Cisatracurium besylate injection, Fresenius Kabi, 10 mg/mL, 20 mL vial, 10 count, NDC 63323-0418-20
    • Cisatracurium besylate injection, Meitheal Pharmaceuticals, 10 mg/mL, 20 mL vial, 10 count, NDC 71288-0713-21
    • Cisatracurium besylate injection, Meitheal Pharmaceuticals, 2 mg/mL, 10 mL vial, 10 count, NDC 71288-0714-11
    • Cisatracurium besylate injection, Meitheal Pharmaceuticals, 2 mg/mL, 5 mL vial, 10 count, NDC 71288-0712-06
    • Cisatracurium besylate injection, Pfizer, 10 mg/mL, 20 mL vial, 10 count, NDC 00409-1103-01
    • Cisatracurium besylate injection, Pfizer, 2 mg/mL, 10 mL vial, 10 count, NDC 00409-1208-01
    • Cisatracurium besylate injection, Pfizer, 2 mg/mL, 5 mL vial, 10 count, NDC 00409-1098-02
    • Cisatracurium besylate injection, Somerset Therapeutics LLC, 10 mg/mL, 20 mL vial, 10 count, NDC 70069-0151-10
    • Cisatracurium besylate injection, Somerset Therapeutics LLC, 2 mg/mL, 10 mL vial, 10 count, NDC 70069-0161-10
    • Cisatracurium besylate injection, Somerset Therapeutics LLC, 2 mg/mL, 5 mL vial, 10 count, NDC 70069-0141-10
    • Cisatracurium besylate injection, Teva, 10 mg/mL, 20 mL vial, 10 count, NDC 00703-2056-03
    • Cisatracurium besylate injection, Teva, 2 mg/mL, 10 mL vial, 10 count, NDC 00703-2045-03
    • Cisatracurium besylate injection, Teva, 2 mg/mL, 5 mL vial, 10 count, NDC 00703-2033-03

Reason for the Shortage

    • Fresenius Kabi has cisatracurium on shortage due to increased demand.
    • Meitheal Pharmaceuticals has cisatracurium on shortage due to increased demand.
    • Pfizer has cisatracurium on shortage due to increased demand.
    • Sandoz had cisatracurium on shortage due to increased demand.
    • Somerset has cisatracurium on shortage due to increased demand.
    • Teva has cisatracurium on shortage due to increased demand.
    • AbbVie did not provide a reason for the shortage of Nimbex.

Available Products

    • Cisatracurium besylate injection, Fresenius Kabi, 2 mg/mL, 10 mL vial, 10 count, NDC 63323-0417-10
    • Cisatracurium besylate injection, Fresenius Kabi, 2 mg/mL, 5 mL vial, 10 count, NDC 63323-0416-05
    • Cisatracurium besylate injection, Sandoz, 10 mg/mL, 20 mL vial, 10 count, NDC 00781-3153-95
    • Cisatracurium besylate injection, Sandoz, 2 mg/mL, 10 mL vial, 10 count, NDC 00781-3152-95
    • Cisatracurium besylate injection, Sandoz, 2 mg/mL, 5 mL vial, 10 count, NDC 00781-3150-95

Estimated Resupply Dates

    • Fresenius Kabi has cisatracurium 10 mg/mL 20 mL vials on back order and the company estimates a release date of 2nd quarter 2021. Check wholesalers for inventory.
    • Meitheal has all cisatracurium presentations on allocation.
    • Pfizer has cisatracurium 2 mg/mL 5 mL vials and 10 mL vials available in limited supply. The 10 mg/mL 20 mL vials are available in limited supply.
    • Somerset has cisatracurium 2 mg/mL 5 mL vials on back order and the company cannot estimate a release date. The 2 mg/mL 10 mL vials and 10 mg/mL 20 mL vials are on intermittent back order and the company is releasing product as it becomes available.
    • Teva has cisatracurium 2 mg/mL 10 mL and 5 mL vials and 10 mg/mL 20 mL vials on allocation.
    • AbbVie has Nimbex 2 mg/mL 5 mL and 10 mL vials on back order and the company cannot estimate a release date. The 10 mg/mL 20 mL vials are on back order and the company cannot estimate a release date.

Updated

Updated October 12, 2020 by Michelle Wheeler, PharmD, Drug Information Specialist. Created April 3, 2020 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2020, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.